Fosamax Cost in New Hampshire 2026: Alendronate Prices, Insurance, and Savings

What Does Fosamax Cost in New Hampshire Right Now?

Generic alendronate averages about $15 per month at New Hampshire retail pharmacies in 2026, making it one of the more affordable prescription osteoporosis treatments available. Brand-name Fosamax carries a manufacturer list price of approximately $80 per month, but virtually no cash-paying patient needs to pay that figure given the wide availability of generics and discount programs.

Alendronate sodium is a bisphosphonate that inhibits osteoclast-mediated bone resorption. The FDA first approved it in 1995 for postmenopausal osteoporosis, and multiple generic manufacturers have offered it since the early 2000s, which is why the cash price has fallen so sharply. The FDA label for alendronate confirms the approved dose of 70 mg once weekly for osteoporosis treatment in postmenopausal women and men.

Price variation across NH pharmacies can be significant. A GoodRx search in Manchester, NH in January 2025 showed 70 mg tablets (four-count, one-month supply) ranging from $9 at Costco to $22 at independent pharmacies, with chains like CVS and Walgreens typically landing between $14 and $18 after coupon. The Fracture Intervention Trial (FIT), published in JAMA in 1998 (N=2,027), demonstrated a 47% relative risk reduction in hip fracture for alendronate 5 mg/day vs. placebo over three years, establishing the clinical rationale that made this the first-line bisphosphonate in virtually every major guideline.

The American Association of Clinical Endocrinologists (AACE) 2020 guidelines list alendronate as a first-line agent for osteoporosis in patients without contraindications, a designation reinforced by its decades-long safety record and low cost.

Does New Hampshire Medicaid Cover Alendronate?

New Hampshire Medicaid does not cover alendronate for osteoporosis under its current preferred drug list (PDL), which is the single most consequential cost issue for low-income NH residents managing this condition. This gap affects a meaningful slice of the roughly 180,000 NH residents enrolled in Medicaid as of 2024.

Medicaid PDL decisions are made at the state level, and New Hampshire's list has historically excluded several bisphosphonates in favor of directing members toward managed-care alternative benefit packages. Patients who believe their clinical situation warrants coverage may request a prior authorization (PA) exception through their managed care organization. The Centers for Medicare and Medicaid Services (CMS) requires states to maintain a PA process, but approval for alendronate in NH Medicaid remains uncommon without documented failure of at least one covered alternative.

Medicare Part D does cover generic alendronate. According to CMS Part D formulary data, most stand-alone Part D plans in NH place generic alendronate on Tier 1 or Tier 2, meaning a monthly copay between $0 and $10 for most enrollees. This makes Medicare-eligible NH patients considerably better positioned than Medicaid-only enrollees.

The National Osteoporosis Foundation (now Bone Health and Osteoporosis Foundation, BHOF) estimates that only about 20% of patients who suffer a hip fracture receive a bone-protective medication in the year following the fracture, a statistic that underscores how coverage gaps translate into preventable harm.

Which Commercial Insurance Plans in New Hampshire Cover Fosamax?

Most major commercial insurance plans available in New Hampshire cover generic alendronate, typically at Tier 1 or Tier 2 with a copay under $20 per month. Brand-name Fosamax lands on Tier 3 or higher at most plans, resulting in significantly higher out-of-pocket costs that rarely justify choosing it over the generic.

Anthem Blue Cross Blue Shield of New Hampshire, Harvard Pilgrim Health Care, and Tufts Health Plan, the three largest commercial carriers in the state, all include generic alendronate on their standard formularies as of 2025 plan year data. Checking your specific plan's formulary on the CMS formulary finder or your insurer's member portal is the most reliable approach, since formulary tiers change annually during open enrollment.

The FDA's guidance on generic drug bioequivalence confirms that approved generic alendronate must meet the same bioequivalence standards as Fosamax, meaning therapeutic substitution by a pharmacist does not alter clinical outcomes. Patients who receive brand Fosamax on a written prescription are routinely substituted to generic at the pharmacy counter unless the prescriber writes "dispense as written."

Employer-sponsored plans governed by ERISA may have different formulary structures than individual market plans. New Hampshire employees should consult their benefits administrator or HR department for plan-specific tier information, particularly if their employer is self-insured.

Is Compounded Alendronate Legal in New Hampshire?

Yes. Compounded alendronate is legal in New Hampshire when prepared by a state-licensed 503A pharmacy operating under a valid patient-specific prescription. This option is particularly relevant for patients who cannot tolerate standard tablet formulations due to esophageal conditions or swallowing difficulties.

Section 503A of the Federal Food, Drug, and Cosmetic Act, as detailed by the FDA, permits licensed pharmacies to compound drugs for individual patients based on a practitioner's prescription. New Hampshire's Board of Pharmacy licenses compounding pharmacies and enforces these federal standards within the state. A 503A compounding pharmacy in NH may prepare alendronate in an alternative concentration or delivery form (such as a liquid suspension for patients who cannot swallow tablets) that is not commercially available.

Cost for compounded alendronate through a 503A pharmacy in New Hampshire may be $0 for qualifying patients in certain clinical or assistance program arrangements, though pricing varies widely by pharmacy and patient circumstance. Patients should confirm whether their prescriber's order specifies a formulation that is genuinely not commercially available, because compounding a product that replicates a commercially available drug without a clinical rationale may not comply with 503A requirements per FDA compounding guidance.

The American Society of Health-System Pharmacists (ASHP) has published standards on compounding practice that NH pharmacies follow, reinforcing that patient safety protocols apply equally to compounded bisphosphonates as to any other compounded medication.

Can You Get Alendronate Via Telehealth in New Hampshire?

Telehealth prescribing of alendronate is permitted in New Hampshire. A licensed New Hampshire prescriber can evaluate a patient via synchronous audio-video telehealth, review bone density results (DXA scan), and issue a valid prescription for alendronate without an in-person visit.

New Hampshire enacted RSA 329:1-d to formalize telehealth prescribing standards, requiring that a prescriber-patient relationship be established before a controlled or non-controlled substance is prescribed remotely. Alendronate is not a controlled substance, so the prescribing standard is more flexible than it would be for, say, a Schedule III drug. A telehealth provider must still conduct a clinically appropriate evaluation, which for osteoporosis typically means reviewing a DXA T-score, fracture history, and relevant lab work.

The U.S. Preventive Services Task Force (USPSTF) recommends screening for osteoporosis in women 65 and older and in younger postmenopausal women at increased risk, a recommendation that telehealth providers can act on by ordering remote DXA and following up with a prescription when indicated. HealthRX clinicians licensed in New Hampshire follow this USPSTF framework as a baseline evaluation standard.

The Endocrine Society's clinical practice guideline on osteoporosis recommends alendronate as a first-line treatment option for postmenopausal women with T-scores at or below -2.5 or with a prior vertebral or hip fracture, criteria that telehealth prescribers can assess from transmitted DXA reports and medical records.

How to Get the Cheapest Price on Alendronate in New Hampshire

The lowest reliable cash price for generic alendronate in New Hampshire runs about $9 to $15 per month when using a discount card or coupon at major retail pharmacies. Several specific strategies reduce cost to near zero.

GoodRx and comparable discount platforms. GoodRx, RxSaver, and NeedyMeds all publish real-time pricing for alendronate at NH pharmacies. These programs function as negotiated discount arrangements, not insurance. Using one at Walmart or Costco pharmacy in Manchester or Concord typically produces the $9 to $15 range cited above.

Manufacturer patient assistance. Merck, the original manufacturer of Fosamax, offers a patient assistance program for brand Fosamax for patients who meet income criteria. Income thresholds are updated annually. Since generic alendronate is so inexpensive, this program has limited practical value for most NH patients unless they specifically require brand Fosamax.

Medicare Extra Help (LIS). NH Medicare beneficiaries with low income may qualify for the Low Income Subsidy program, which reduces Part D drug costs to $0 to $4 per month for Tier 1 drugs. CMS administers Extra Help applications through the Social Security Administration.

340B program pharmacies. Federally qualified health centers (FQHCs) and other 340B-eligible entities in New Hampshire can dispense alendronate at significantly reduced cost to qualifying patients. HRSA's 340B database lists covered entities by state, including several in Manchester, Nashua, and Concord.

Compounded alendronate. As noted above, a 503A pharmacy compounding a patient-specific formulation may provide it at $0 in specific assistance arrangements. This requires a valid prescription documenting clinical need for a non-commercially-available formulation.

The FIT trial data showed that three years of alendronate therapy reduced vertebral fracture risk by 55% (relative risk 0.53; 95% CI, 0.41 to 0.68) in women with existing vertebral fractures, meaning the clinical cost of foregoing treatment, measured in fractures, hospitalizations, and mortality, vastly exceeds the $15 monthly drug cost.

Understanding the Clinical Evidence Behind Alendronate

Alendronate's evidence base is among the strongest of any osteoporosis drug, which is part of why every major guideline lists it first. The Fracture Intervention Trial (FIT) enrolled 2,027 postmenopausal women with low bone mass and at least one existing vertebral fracture and followed them for approximately 36 months. The alendronate group achieved a 47% relative risk reduction in hip fracture (P<0.001) and a 55% reduction in clinical vertebral fracture compared to placebo, as published in JAMA 1998.

A separate FIT arm involving 4,432 women without baseline vertebral fracture found a 44% reduction in clinical fracture in the subgroup with femoral neck T-scores below -2.5, reported in JAMA 1998 (Black et al.). These two FIT publications remain the foundational regulatory and clinical basis for alendronate's use.

The AACE/ACE 2020 postmenopausal osteoporosis guidelines state: "Alendronate is recommended as a first-line therapy for postmenopausal women with osteoporosis at high fracture risk." This direct guideline language reflects more than two decades of consistent trial replication. The Cochrane Collaboration's systematic review of bisphosphonates for osteoporosis, available at Cochrane Library, pooled data from 11 randomized controlled trials and found alendronate reduced vertebral fractures by approximately 45% and non-vertebral fractures by roughly 16% vs. placebo.

Duration of therapy matters. The FLEX trial (N=1,099), published in JAMA 2006, examined women who had taken alendronate for five years and found that continuing for an additional five years reduced clinical vertebral fracture risk by 55% vs. switching to placebo, though hip fracture risk was similar between groups. Most guidelines recommend reassessing after five years and considering a drug holiday in lower-risk patients, a conversation that a telehealth prescriber in NH can conduct during a scheduled follow-up visit.

Osteonecrosis of the jaw (ONJ) and atypical femoral fractures (AFF) are rare but recognized adverse events. The FDA updated the alendronate label to include AFF warnings in 2011 following a review of post-marketing data. The American Society for Bone and Mineral Research (ASBMR) estimated AFF incidence at 3.2 to 50 per 100,000 person-years of bisphosphonate use, a rate that must be weighed against the substantially higher incidence of osteoporotic fractures in untreated populations.

How Alendronate Fits Into NH Osteoporosis Management

Osteoporosis affects an estimated 10 million Americans, with another 44 million having low bone density, according to BHOF prevalence data. New Hampshire's older demographic, with 18.5% of residents aged 65 or older per CDC state data, places the state above the national average for osteoporosis prevalence.

DXA screening is the diagnostic standard. The USPSTF recommends DXA for all women 65 and older and for younger postmenopausal women whose 10-year fracture probability equals or exceeds that of a 65-year-old white woman without additional risk factors. New Hampshire has DXA facilities in every major city, and results can be shared with a telehealth prescriber by fax or patient portal upload.

FRAX, the WHO fracture risk assessment tool, helps guide treatment decisions when T-scores fall in the osteopenia range (-1.0 to -2.5). The WHO FRAX methodology incorporates age, sex, body mass index, prior fracture, parental hip fracture, smoking, glucocorticoid use, rheumatoid arthritis, secondary osteoporosis causes, and alcohol use to estimate 10-year fracture probability. A 10-year hip fracture probability at or above 3%, or major osteoporotic fracture probability at or above 20%, typically triggers a recommendation to initiate pharmacotherapy per BHOF guidelines.

Calcium and vitamin D adequacy form the foundation of any osteoporosis treatment plan. The NIH Office of Dietary Supplements recommends 1 to 200 mg calcium daily for women over 50 and 1 to 000 IU to 2 to 000 IU vitamin D3 daily depending on baseline serum 25-hydroxyvitamin D levels. Alendronate does not replace these; it works alongside adequate calcium and vitamin D, and the FIT trial protocol supplemented all participants with 500 mg calcium and 250 IU vitamin D daily.

Adherence is the single biggest practical challenge with alendronate. Patients must take the tablet on an empty stomach first thing in the morning, with at least 8 ounces of plain water, and remain upright for at least 30 minutes afterward to minimize esophageal irritation. A 2003 study in Osteoporosis International found that adherence below 80% of prescribed doses significantly reduced fracture protection. Patients who cannot reliably follow the oral bisphosphonate protocol may be candidates for IV zoledronic acid (Reclast, 5 mg once yearly), an option that a telehealth prescriber in NH can also initiate with an appropriate infusion referral.

Practical Steps for New Hampshire Patients in 2026

Getting started with alendronate in New Hampshire requires a valid prescription from a licensed NH provider, a DXA scan or documented clinical indication, and a pharmacy. The workflow can be completed without a single in-person visit for most patients.

Step one: obtain a DXA scan at any NH imaging center. Most accept referrals from telehealth providers and transmit results electronically. Step two: schedule a telehealth visit with an NH-licensed prescriber who reviews the DXA T-score, calculates FRAX probability, and evaluates contraindications (active upper GI disease, inability to sit upright, renal impairment with GFR <35 mL/min per the FDA label). Step three: present the prescription at any NH retail pharmacy with a GoodRx coupon or discount card to pay approximately $9 to $15 per month.

Patients on Medicaid with no other coverage option should ask their prescriber to document failure or contraindication to any PDL-covered osteoporosis alternative and submit a prior authorization request. If denied, the NH Medicaid fair hearing process, administered through NH DHHS, provides an appeals path.

A one-month supply of generic alendronate 70 mg at the lowest NH pharmacy price costs less than a single copay at many urgent care facilities. The fracture it helps prevent could mean weeks of hospitalization, rehabilitation costs exceeding $30,000, and a 20 to 24% one-year mortality risk following hip fracture in older adults, per data published in JBMR (2011).